These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15330171)
41. Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice. Steinberg T; Ohlschläger P; Sehr P; Osen W; Gissmann L Vaccine; 2005 Jan; 23(9):1149-57. PubMed ID: 15629358 [TBL] [Abstract][Full Text] [Related]
42. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Brulet JM; Maudoux F; Thomas S; Thielemans K; Burny A; Leo O; Bex F; Hallez S Eur J Immunol; 2007 Feb; 37(2):376-84. PubMed ID: 17274002 [TBL] [Abstract][Full Text] [Related]
43. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Li Y; Subjeck J; Yang G; Repasky E; Wang XY Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072 [TBL] [Abstract][Full Text] [Related]
44. [Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice]. Luo WF; Han LQ; Ren J; Tian HW; Lu ZH; Zhao L; Gu SY; Ruan L Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):335-9. PubMed ID: 12921560 [TBL] [Abstract][Full Text] [Related]
45. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Dell K; Klein C; Gissmann L Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528 [TBL] [Abstract][Full Text] [Related]
46. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Liu B; Ye D; Song X; Zhao X; Yi L; Song J; Zhang Z; Zhao Q Vaccine; 2008 Mar; 26(10):1387-96. PubMed ID: 18272260 [TBL] [Abstract][Full Text] [Related]
47. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Smahel M; Síma P; Ludvíková V; Marinov I; Pokorná D; Vonka V Vaccine; 2003 Mar; 21(11-12):1125-36. PubMed ID: 12559790 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours. Chandy AG; Nurkkala M; Josefsson A; Eriksson K Vaccine; 2007 Aug; 25(32):6037-46. PubMed ID: 17629599 [TBL] [Abstract][Full Text] [Related]
49. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060 [TBL] [Abstract][Full Text] [Related]
50. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Mackova J; Kutinova L; Hainz P; Krystofova J; Sroller V; Otahal P; Gabriel P; Nemeckova S Int J Oncol; 2004 Jun; 24(6):1581-8. PubMed ID: 15138603 [TBL] [Abstract][Full Text] [Related]
51. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope. Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358 [TBL] [Abstract][Full Text] [Related]
52. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807 [TBL] [Abstract][Full Text] [Related]
53. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines. Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569 [TBL] [Abstract][Full Text] [Related]
54. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265 [TBL] [Abstract][Full Text] [Related]
55. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. Lee DW; Anderson ME; Wu S; Lee JH Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129 [TBL] [Abstract][Full Text] [Related]